biotech investing Mereo BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate Highlights
biotech investing Sentynl Therapeutics and Mereo BioPharma Announce Option and License Agreement for alvelestat in Alpha-1 Antitrypsin Deficiency-Associated Lung Disease
biotech investing Mereo BioPharma and Sentynl Therapeutics Announce Option and License Agreement for alvelestat in Alpha-1 Antitrypsin Deficiency-Associated Lung Disease
biotech investing Mereo BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate Updates
biotech investing Mereo BioPharma Reports Full Year 2025 Financial Results and Provides Corporate Highlights
biotech investing Mereo BioPharma Announces Phase 3 ORBIT and COSMIC Results for Setrusumab in Osteogenesis Imperfecta
biotech investing Mereo BioPharma Reports Third Quarter 2025 Financial Results and Provides Corporate HighlightsÂ
CoTec and Battery Mineral Resources Enter Strategic Partnership to Unlock Additional Copper Production and Growth Opportunities at Punitaqui
Westport Rebrands as Aetherion Technologies, Focused on Accelerating Proven Solutions for Heavy-Duty Clean Transport
